Literature DB >> 23283943

5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses.

Che C Colpitts1, Alexey V Ustinov, Raquel F Epand, Richard M Epand, Vladimir A Korshun, Luis M Schang.   

Abstract

Entry of enveloped viruses requires fusion of viral and cellular membranes. Fusion requires the formation of an intermediate stalk structure, in which only the outer leaflets are fused. The stalk structure, in turn, requires the lipid bilayer of the envelope to bend into negative curvature. This process is inhibited by enrichment in the outer leaflet of lipids with larger polar headgroups, which favor positive curvature. Accordingly, phospholipids with such shape inhibit viral fusion. We previously identified a compound, 5-(perylen-3-yl)ethynyl-2'-deoxy-uridine (dUY11), with overall shape and amphipathicity similar to those of these phospholipids. dUY11 inhibited the formation of the negative curvature necessary for stalk formation and the fusion of a model enveloped virus, vesicular stomatitis virus (VSV). We proposed that dUY11 acted by biophysical mechanisms as a result of its shape and amphipathicity. To test this model, we have now characterized the mechanisms against influenza virus and HCV of 5-(perylen-3-yl)ethynyl-arabino-uridine (aUY11), which has shape and amphipathicity similar to those of dUY11 but contains an arabino-nucleoside. aUY11 interacted with envelope lipids to inhibit the infectivity of influenza virus, hepatitis C virus (HCV), herpes simplex virus 1 and 2 (HSV-1/2), and other enveloped viruses. It specifically inhibited the fusion of influenza virus, HCV, VSV, and even protein-free liposomes to cells. Furthermore, aUY11 inhibited the formation of negative curvature in model lipid bilayers. In summary, the arabino-derived aUY11 and the deoxy-derived dUY11 act by the same antiviral mechanisms against several enveloped but otherwise unrelated viruses. Therefore, chemically unrelated compounds of appropriate shape and amphipathicity target virion envelope lipids to inhibit formation of the negative curvature required for fusion, inhibiting infectivity by biophysical, not biochemical, mechanisms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283943      PMCID: PMC3624206          DOI: 10.1128/JVI.02882-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.

Authors:  Mireille R St Vincent; Che C Colpitts; Alexey V Ustinov; Muhammad Muqadas; Michael A Joyce; Nicola L Barsby; Raquel F Epand; Richard M Epand; Stanislav A Khramyshev; Olga A Valueva; Vladimir A Korshun; D Lorne J Tyrrell; Luis M Schang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-07       Impact factor: 11.205

2.  A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry.

Authors:  R Liu; M Tewari; R Kong; R Zhang; P Ingravallo; R Ralston
Journal:  Antiviral Res       Date:  2010-02-13       Impact factor: 5.970

3.  Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes.

Authors:  José Villalaín
Journal:  J Phys Chem B       Date:  2010-07-01       Impact factor: 2.991

4.  PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Authors:  Ana Maria Chamoun; Karuppiah Chockalingam; Michael Bobardt; Rudo Simeon; Jinhong Chang; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

5.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

Authors:  Kelly Huang; Len Incognito; Xing Cheng; Nancy D Ulbrandt; Herren Wu
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

7.  The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Authors:  Thomas Krey; Jacques d'Alayer; Carlos M Kikuti; Aure Saulnier; Laurence Damier-Piolle; Isabelle Petitpas; Daniel X Johansson; Rajiv G Tawar; Bruno Baron; Bruno Robert; Patrick England; Mats A A Persson; Annette Martin; Félix A Rey
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

8.  Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol.

Authors:  Elodie Teissier; Giorgia Zandomeneghi; Antoine Loquet; Dimitri Lavillette; Jean-Pierre Lavergne; Roland Montserret; François-Loïc Cosset; Anja Böckmann; Beat H Meier; François Penin; Eve-Isabelle Pécheur
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

9.  Rabies virus-induced membrane fusion pathway.

Authors:  Y Gaudin
Journal:  J Cell Biol       Date:  2000-08-07       Impact factor: 10.539

Review 10.  Targeting cell entry of enveloped viruses as an antiviral strategy.

Authors:  Elodie Teissier; François Penin; Eve-Isabelle Pécheur
Journal:  Molecules       Date:  2010-12-30       Impact factor: 4.411

View more
  22 in total

1.  The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses.

Authors:  Frederic Vigant; Axel Hollmann; Jihye Lee; Nuno C Santos; Michael E Jung; Benhur Lee
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

2.  Surfactin Inhibits Membrane Fusion during Invasion of Epithelial Cells by Enveloped Viruses.

Authors:  Lvfeng Yuan; Shuai Zhang; Yongheng Wang; Yuchen Li; Xiaoqing Wang; Qian Yang
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

3.  A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans.

Authors:  Che C Colpitts; Luis M Schang
Journal:  J Virol       Date:  2014-04-30       Impact factor: 5.103

Review 4.  Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

Authors:  Thomas Pietschmann
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

5.  Entry Inhibitors of Hepatitis C Virus.

Authors:  Xi-Jing Qian; Zhong-Tian Qi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 7.  How hepatitis C virus invades hepatocytes: the mystery of viral entry.

Authors:  Yong-Zhe Zhu; Xi-Jing Qian; Ping Zhao; Zhong-Tian Qi
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 8.  Photosensitizing Antivirals.

Authors:  Kseniya A Mariewskaya; Anton P Tyurin; Alexey A Chistov; Vladimir A Korshun; Vera A Alferova; Alexey V Ustinov
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

Review 9.  Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.

Authors:  Che C Colpitts; Thomas F Baumert
Journal:  Hepatol Int       Date:  2016-04-05       Impact factor: 9.029

10.  A High-Throughput Flow Cytometry Screen Identifies Molecules That Inhibit Hantavirus Cell Entry.

Authors:  Tione Buranda; Catherine Gineste; Yang Wu; Virginie Bondu; Dominique Perez; Kaylin R Lake; Bruce S Edwards; Larry A Sklar
Journal:  SLAS Discov       Date:  2018-04-02       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.